<ѻý>Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancerѻý> Docetaxel-enzalutamide regimen may offer another option for men who progressed on AR inhibitor Feb 18, 2022
<ѻý>Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPCѻý> In one case, rPFS benefit was seen regardless of HRR mutational status Feb 18, 2022
<ѻý>Ablating High-Grade Anal Lesions Thwarts Progression to Cancerѻý> Screening followed by aggressive therapy shows benefit in phase III ANCHOR study Feb 17, 2022
<ѻý>Darolutamide Improves OS in Metastatic Prostate Cancerѻý> The AR inhibitor plus standard therapy led to a 32% reduced risk of death versus placebo Feb 17, 2022
<ѻý>Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesotheliomaѻý> Disease control in 54% of patients in first clinical evaluation of abemaciclib Feb 17, 2022
<ѻý>Sotorasib Impresses in Advanced Pancreatic Cancerѻý> ORR of 21% in heavily pretreated patients with a KRAS G12C mutation Feb 16, 2022
<ѻý>Third Person 'Cured' of HIV via Transplantѻý> U.S. woman with leukemia gets cord blood resistant to HIV Feb 16, 2022
<ѻý>Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drugѻý> Significant improvements in OS, PFS with durvalumab after CRT for unresectable disease Feb 15, 2022
<ѻý>Women More Likely to Experience Severe Toxicity of Cancer Treatmentsѻý> Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<ѻý>Pembrolizumab Shows Promise in Advanced Anal Cancerѻý> PD-1 inhibitor may be an option for those who have no options Feb 11, 2022
<ѻý>Active Cellular Immunotherapy Disappoints in Metastatic Prostate Cancerѻý> In combination with chemotherapy, no OS benefit seen with DCVAC/PCa over placebo Feb 10, 2022
<ѻý>Illusionist Criss Angel's Son's Acute Leukemiaѻý> Famed magician speaks about the long battle Feb 09, 2022
<ѻý>Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancerѻý> Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
<ѻý>Did Improved Treatment for Cervical Abnormalities Affect Birth Outcomes?ѻý> Swedish data found risks for adverse outcomes remain higher, but declined over time Feb 07, 2022
<ѻý>Dear Blood Donors, You've Given Me the Gift of Lifeѻý> I offer my gratitude through acceptance, acknowledgement, and reflection Feb 06, 2022
<ѻý>FDA Concerned About Safety of Lymphoma Drugѻý> Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
<ѻý>Genetic Role of Alcohol-Cancer Link Strengthenedѻý> In study from China, two common variants associated with lower risk of cancer in men Feb 01, 2022
<ѻý>When Strangers Deliver Bad News to Patientsѻý> All too often, I end up giving prognoses to patients I barely know Jan 31, 2022
<ѻý>Dual HER2 Therapy Active in Previously Treated Lung Cancerѻý> Disease control in 87% of HER2-mutant NSCLC treated with trastuzumab, pertuzumab, docetaxel Jan 27, 2022
<ѻý>An 'Intriguing Failure' in Advanced, Pre-Treated GISTѻý> Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity Jan 26, 2022
<ѻý>Trial Data Confirm Heightened Risks With JAK Inhibitorѻý> May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
<ѻý>Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcomaѻý> Median OS and PFS improved versus paclitaxel-ifosfamide Jan 25, 2022
<ѻý>GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancerѻý> Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer Jan 24, 2022
<ѻý>Adagrasib Promising in KRAS-Mutant GI Cancersѻý> The KRAS G12C inhibitor showed a disease control rate of 100% in small study Jan 24, 2022
<ѻý>Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapyѻý> Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade Jan 23, 2022
<ѻý>Immunotherapy Not Additive to Standard of Care for Untreated Metastatic CRCѻý> No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab Jan 23, 2022
<ѻý>Potential New First-Line Options for Unresectable Hepatocellular Carcinomaѻý> Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib Jan 22, 2022
<ѻý>Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancersѻý> Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer Jan 21, 2022
<ѻý>More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancerѻý> Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression Jan 21, 2022
<ѻý>We've Never Really Understood the Prostateѻý> Wolinsky reviews Ericka Johnson's new book, A Cultural Biography of the Prostate Jan 19, 2022
<ѻý>Growing Controversy Over 'Skinny' Labeling for Generic Drugsѻý> What's at stake in legal battles over patent-avoiding approval pathway for generics Jan 17, 2022
<ѻý>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Upѻý> More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<ѻý>Earlier Colorectal Screening Bolstered by Real-World Dataѻý> Researchers of a national registry study say "45 is now the new 50" Jan 10, 2022
<ѻý>Melanoma Patient on Immunotherapy Develops Severe Dermatitisѻý> Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<ѻý>Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiationѻý> Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
<ѻý>Finally, a 'New Standard' for Severe Aplastic Anemiaѻý> After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
<ѻý>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survivalѻý> Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
<ѻý>In Early Prostate Cancer, Black Men Do Better With Radiotherapy Than White Menѻý> "Unexpected" finding holds even though Black men are more likely to have high-risk features Dec 29, 2021
<ѻý>Living History: 50 Years After the Birth of National Cancer Centersѻý> New book examines the progress 50 years following the National Cancer Act of 1971 Dec 22, 2021